Table 2.

Baseline characteristics of patients in three independent validation cohorts

Characteristics	Whole cohort	Low risk	High risk	p
TCGA cohort	(n = 321)	(n = 78)	(n = 243)
Gender				0.772
Male	204 (63.55)	48 (61.54)	156 (64.20)
Female	117 (36.45)	30 (38.46)	87 (35.80)
Age				0.995
< 65 years	146 (45.48)	36 (46.15)	110 (45.27)
≥ 65 years	175 (54.52)	42 (53.85)	133 (54.73)
TNM stagea				0.253
I	44 (13.71)	13 (16.67)	31 (12.76)
II	104 (32.40)	18 (23.08)	86 (35.39)
III	132 (41.12)	36 (46.15)	96 (39.51)
IV	29 (9.03)	7 (8.97)	22 (9.05)
WHO classification				0.085
Intestinal/tubular	125 (38.94)	34 (43.59)	91 (37.45)
Diffuse	57 (17.76)	15 (19.23)	42 (17.28)
Mucinous/signet ring cell	26 (8.10)	1 (1.28)	25 (10.29)
Others	113 (35.20)	28 (35.90)	85 (34.98)

ACRG cohort	(n = 300)	(n = 219)	(n = 81)
Gender				0.950
Male	199 (66.33)	146 (66.67)	53 (65.43)
Female	101 (33.67)	73 (33.33)	28 (34.57)
Age				0.999
< 65 years	161 (53.67)	118 (53.88)	43 (53.09)
≥ 65 years	139 (46.33)	101 (46.12)	38 (46.91)
TNM stage				0.097
I	30 (10.00)	27 (12.32)	3 (3.70)
II	97 (32.33)	73 (33.33)	24 (29.63)
III	96 (32.00)	67 (30.59)	29 (35.80)
IV	77 (25.67)	52 (23.74)	25 (30.86)
Lauren classification				0.141
Diffuse	135 (45.00)	91 (41.55)	44 (54.32)
Intestinal	146 (48.67)	113 (51.60)	33 (40.74)
Mixed	19 (6.33)	15 (6.84)	4 (4.93)

CHEM cohort	(n = 136)	(n = 46)	(n = 90)
Gender				0.709
Male	93 (68.38)	30 (65.22)	63 (70.00)
Female	43 (31.62)	16 (34.78)	27 (30.00)
Age				0.726
< 65 years	87 (63.97)	28 (60.87)	59 (65.56)
≥ 65 years	49 (36.03)	18 (39.13)	31 (34.44)
TNM stage				0.496
II	36 (26.47)	15 (32.61)	21 (23.33)
III	63 (46.32)	19 (41.30)	44 (48.89)
IV	37 (27.21)	12 (26.09)	25 (27.78)
Lauren classificationa				0.075
Diffuse	30 (22.06)	15 (32.61)	15 (16.67)
Intestinal	95 (69.85)	27 (58.70)	68 (75.56)
Mixed	7 (5.15)	3 (6.52)	4 (4.44)

^aTwelve patients with unavailable stage information in the TCGA cohort and four patients with unavailable Lauren classification information in the CHEM cohort were excluded from the comparison